These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9704618)

  • 1. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
    Mangano WE; Cagle PT; Churg A; Vollmer RT; Roggli VL
    Am J Clin Pathol; 1998 Aug; 110(2):191-9. PubMed ID: 9704618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis of desmoplastic malignant mesothelioma.
    Colby TV
    Am J Clin Pathol; 1998 Aug; 110(2):135-6. PubMed ID: 9704609
    [No Abstract]   [Full Text] [Related]  

  • 4. Desmoplastic malignant mesothelioma: two cases and a literature review.
    Hirano H; Maeda H; Sawabata N; Okumura Y; Takeda S; Maekura R; Ito M; Maeda T; Nakane S; Uematsu K
    Med Electron Microsc; 2003 Sep; 36(3):173-8. PubMed ID: 14505061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
    Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
    Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The separation of benign and malignant mesothelial proliferations.
    Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
    Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
    Hashimoto K; Okuma Y; Hosomi Y; Hishima T
    BMC Cancer; 2016 Sep; 16(1):718. PubMed ID: 27599565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autopsy case of sarcomatoid malignant pleural mesothelioma].
    Ogura H; Naoki K; Togashi I; Kunikane H; Okamoto H; Hida N; Narita Y; Kase M; Oosawa H; Oomori T; Watanabe K
    Nihon Kokyuki Gakkai Zasshi; 2006 Oct; 44(10):689-94. PubMed ID: 17087333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spindle cell tumors of the pleura: differential diagnosis.
    Rdzanek M; Fresco R; Pass HI; Carbone M
    Semin Diagn Pathol; 2006 Feb; 23(1):44-55. PubMed ID: 17044195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.
    Kwee WS; Veldhuizen RW; Golding RP; Mullink H; Stam J; Donner R; Boon ME
    Virchows Arch A Pathol Anat Histol; 1982; 397(3):287-99. PubMed ID: 6186071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas.
    Churg A; Cagle P; Colby TV; Corson JM; Gibbs AR; Hammar S; Ordonez N; Roggli VL; Tazelaar HD; Travis WD; Wick M;
    Am J Surg Pathol; 2011 Dec; 35(12):1823-9. PubMed ID: 21959310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
    Epstein JI; Budin RE
    Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual presentations of thoracic tumors: Case 2. Malignant mesothelioma mimicking rheumatoid pleurisy.
    Nanke Y; Akama H; Hebisawa A; Suzuki M; Akagawa S; Tateishi M; Yamagata H; Kawai T; Kamatani N
    J Clin Oncol; 2001 Sep; 19(17):3782-4. PubMed ID: 11533103
    [No Abstract]   [Full Text] [Related]  

  • 16. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.
    Adams VI; Unni KK; Muhm JR; Jett JR; Ilstrup DM; Bernatz PE
    Cancer; 1986 Oct; 58(7):1540-51. PubMed ID: 3742473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
    Kato Y; Tsuta K; Seki K; Maeshima AM; Watanabe S; Suzuki K; Asamura H; Tsuchiya R; Matsuno Y
    Mod Pathol; 2007 Feb; 20(2):215-20. PubMed ID: 17192790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
    Derakhshan F; Ionescu D; Cheung S; Churg A
    Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.